Skip to main content

Table 1 Baseline characteristics of included 451 patients with HCC and comparison of factors between patients with and without severe PHLF

From: Impact of aspartate aminotransferase–to–platelet ratio index based score to assess posthepatectomy liver failure in patients with hepatocellular carcninoma

Variables

All patients (n = 451)

Severe PHLF

P value

No (n = 421)

Yes (n = 30)

Age (years)

71 (35–91)

71 (35–91)

68 (35–82)

0.2788

Sex, female/male/female

146/305

139/282

7/23

0.2734

BMI (kg/m2)

23.2 (13.4–34.1)

23.3 (13.4–34.1)

21.6 (19.2–29.0)

0.0237*

Etiology

HBV/HCV/HBV + HCV/NBNC

65/280/5/101

59/259/5/98

6/21/0/3

0.3103

Albumin (g/dL)

4.0 (2.5–5.1)

4.0 (2.5–5.1)

3.7 (3.0–4.9)

0.0054*

Total bilirubin (mg/dL)

0.7 (0.2–2.0)

0.7 (0.2–2.0)

1.0 (0.4–1.9)

0.0012*

AST (IU/L)

37 (8–252)

36 (8–252)

55 (32–150)

< 0.0001**

ALT (IU/L)

34 (6–312)

33 (6–312)

47 (20–245)

0.0004**

Platelet count (× 109/L)

134 (24–660)

139 (24–530)

89 (33–660)

0.0019*

PT (%)

91.5 (46.3–130.3)

91.9 (46.3–130.3)

82.3 (49.2–107.9)

0.0019*

INR

1.06 (0.88–1.67)

1.05 (0.88–1.67)

1.11 (0.97–1.56)

0.0023*

Creatinine (mg/dL)

0.76 (0.20–7.11)

0.76 (0.2–7.11)

0.84 (0.5–6.0)

0.0152*

Urine nitrogen (mg/dL)

14.8 (5.3–48.9)

14.8 (5.3–48.9)

14.7 (9.3–47.5)

0.6681

ICG-R15 (%)

16.8 (0.9–67.0)

16.5 (0.9–67.0)

24.0 (3.9–54.6)

0.0068*

PALBI

− 2.66 (− 3.43 to − 1.31)

− 2.67 (− 3.43 to − 1.65)

(− 2.45 (− 3.14 to (− 1.31)

0.0055*

APRI

0.96 (0.09–12.7)

0.91 (0.09–12.7)

2.16 (0.19–8.99)

< 0.0001**

FIB-4 index

3.3 (0.5–100.6)

3.2 (0.5–100.6)

6.5 (0.7–22.2)

< 0.0001**

ALPlat index

500 (322–975)

504 (322–932)

466 (331–975)

0.0016*

MELD

7.3 (6.4–15.5)

7.3 (6.4–15.1)

8.9 (6.4–15.5)

0.0005**

Child-Pugh grade A/B

438/13

410/11

28/2

0.1998

Blood loss (mL)

270 (0–3330)

260 (0–2800)

695 (33–3330)

0.0003**

Operating time (min)

214 (60–633)

212 (60–630)

276 (90–633)

0.0014*

Extent of hepatectomy

Minor/major

406/45

384/37

22/8

0.0016*

AFP (ng/mL)

11.7 (1.0–93721)

11.2 (1.0–46262.6)

39.3 (2.1–93721)

0.0014*

DCP (mAU/mL)

24 (0.01–109830)

24 (0.01–43253)

42 (0.03–109830)

0.1851

BCLC grading

0/A/B

109/261/81

105/245/71

4/16/10

0.0522

TNM staging

I–II/III–IV

213/238

206/215

7/23

0.0114*

Tumor size (cm)

2.4 (0.5–13.0)

2.3 (0.5–13.0)

3.0 (1.5–12.0)

0.0069*

Solitary/multiple

326/125

309/112

17/13

0.0479*

Poorly differentiation

114 (25.3%)

105 (24.9%)

9 (30.0%)

0.5379

Microscopic vascular invasion

35 (7.8%)

34 (8.1%)

1 (3.3%)

0.3482

Microscopic intrahepatic metastasis

63 (14.0)

55 (13.1%)

8 (26.7%)

0.0379*

Liver cirrhosis (F4)

206 (45.7%)

187 (44.4%)

19 (63.3%)

0.0445*

  1. Data are presented as N or median (range). AFP alpha-fetoprotein, ALPlat index platelet count + 90 × albumin, ALT alanine aminotransferase, APRI AST-to-platelet ratio index, AST asparate aminotransferase, BCLC Barcelona Clinic Liver Cancer, BMI body mass index, CRP C-reactive protein, DCP des-γ-carboxyprothrombin, FIB-4 fibrosis-4, HBV hepatitis B virus, HCV hepatitis C virus, ICG-R15 indocyanine green dye retention rate at 15 min, MELD model for end-stage liver disease, PALBI platelet-albumin-bilirubin, PHLF posthepatectomy liver failure, PT prothrombin time, TNM tumor, node, metastasis *P < 0.05 and **P < 0.001